These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17290298)

  • 41. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fine tuning the immune response with PI3K.
    Fruman DA; Bismuth G
    Immunol Rev; 2009 Mar; 228(1):253-72. PubMed ID: 19290933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis.
    Chakravarty SD; Poulikakos PI; Ivashkiv LB; Salmon JE; Kalliolias GD
    Clin Immunol; 2013 Jul; 148(1):66-78. PubMed ID: 23651870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation.
    Parry RV; Riley JL; Ward SG
    Trends Immunol; 2007 Apr; 28(4):161-8. PubMed ID: 17336157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
    Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
    Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.
    Medina-Tato DA; Ward SG; Watson ML
    Immunology; 2007 Aug; 121(4):448-61. PubMed ID: 17614878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases.
    Ghigo A; Damilano F; Braccini L; Hirsch E
    Bioessays; 2010 Mar; 32(3):185-196. PubMed ID: 20162662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.
    Lanni TB; Greene KL; Kolz CN; Para KS; Visnick M; Mobley JL; Dudley DT; Baginski TJ; Liimatta MB
    Bioorg Med Chem Lett; 2007 Feb; 17(3):756-60. PubMed ID: 17095227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Role of PI3K Isoforms in Autoimmune Disease.
    Ward SG
    Curr Top Microbiol Immunol; 2022; 436():337-347. PubMed ID: 36243851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphoinositide 3-kinase δ (PI3Kδ) in respiratory disease.
    Stokes CA; Condliffe AM
    Biochem Soc Trans; 2018 Apr; 46(2):361-369. PubMed ID: 29523773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
    Banham-Hall E; Clatworthy MR; Okkenhaug K
    Open Rheumatol J; 2012; 6():245-58. PubMed ID: 23028409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PI3K inhibitors as potential therapeutics for autoimmune disease.
    Ball J; Archer S; Ward S
    Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management.
    Jeong JS; Kim JS; Kim SR; Lee YC
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31323822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives.
    Vyas P; Vohora D
    Curr Drug Targets; 2017; 18(14):1622-1640. PubMed ID: 27739372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis.
    Drexler SK; Kong PL; Wales J; Foxwell BM
    Arthritis Res Ther; 2008; 10(5):216. PubMed ID: 18947379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of rheumatoid arthritis and other related conditions by provoking a mild infection to be controlled by the immune system itself.
    Halabe Bucay A
    Med Hypotheses; 2007; 69(1):27-9. PubMed ID: 17280795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
    Camps M; Rückle T; Ji H; Ardissone V; Rintelen F; Shaw J; Ferrandi C; Chabert C; Gillieron C; Françon B; Martin T; Gretener D; Perrin D; Leroy D; Vitte PA; Hirsch E; Wymann MP; Cirillo R; Schwarz MK; Rommel C
    Nat Med; 2005 Sep; 11(9):936-43. PubMed ID: 16127437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging roles of rhomboid-like pseudoproteases in inflammatory and innate immune responses.
    Luo WW; Shu HB
    FEBS Lett; 2017 Oct; 591(20):3182-3189. PubMed ID: 28815577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.